Last quarter (Q3 2022), Yumanity Therapeutics's total revenue was $1.40M, a decrease of -14.25% from the same quarter last year. In Q3, Yumanity Therapeutics's net income was $-3.36M. See Yumanity Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 21	Dec 20	Dec 19
Total Revenue	$ 4.84M	$ 8.04M	$ 6.90M	$ 0.00
Cost of Revenue	-	-	-	-
Gross Profit	-	-	-	-
Operating Expense	$ 32.11M	$ 46.79M	$ 34.19M	$ 30.03M
Operating Income	$ -27.26M	$ -38.74M	$ -27.30M	$ -30.03M
Net Non Operating Interest Income Expense	$ -635.00K	$ -1.89M	$ -1.93M	$ -679.00K
Other Income Expense	$ -4.10M	$ 1.13M	$ -28.26M	$ -499.00K
Pretax Income	$ -32.00M	$ -39.50M	$ -57.49M	$ -31.21M
Tax Provision	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-
Net Income Common Stockholders	$ -32.00M	$ -39.50M	$ -50.79M	$ -31.21M
Basic EPS	$ -3.00	$ -3.84	$ -21.57	$ -3.09
Diluted EPS	$ -3.00	$ -3.84	$ -21.57	$ -3.09
Basic Average Shares	$ 42.87M	$ 10.28M	$ 2.35M	$ 10.09M
Diluted Average Shares	$ 42.87M	$ 10.28M	$ 2.35M	$ 10.09M
Dividend Per Share	-	-	-	-
Total Operating Income As Reported	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-
Rent Expense Supplemental	-	-	-	-
Total Expenses	$ 32.11M	$ 46.79M	$ 34.19M	$ 30.03M
Net Income From Continuing And Discontinued Operation	$ -32.00M	$ -39.50M	$ -57.49M	$ -31.21M
Normalized Income	$ -27.90M	$ -40.64M	$ -29.22M	$ -30.71M
Interest Expense	$ 982.00K	$ 1.89M	$ 1.93M	$ 1.21M
EBIT	$ -31.02M	$ -37.61M	$ -55.56M	$ -30.00M
EBITDA	$ -30.80M	$ -36.98M	$ -54.79M	$ -28.94M

Currency in USD

Yumanity Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing